Shares of Intuitive Surgical soared on Wednesday making it TheStreet's Move of the Day.
PTC Therapeutics expects conditional approval from European regulators this summer for its Duchenne muscular dystrophy (DMD) treatment Translarna.
Puma Biotechnology (PBYI) shares more than tripled after the company released top-line results from the Phase 3 trial of its breast cancer treatment neratinib.
Puma is why so many investors love to speculate on biotech stocks. A contrarian trade against a heavily expected outcome can return a fortune.
Biogen Idec (BIIB) reported earnings and revenue well ahead of analysts expectations and raised their top line full year guidance by 13% points.
TheStreet's Jim Cramer says that Puma Biotechnology reported incredible test results, and the big move in the share price shows how hard it is to value biotech.
Bayer CropSciences' corn seed treatments and flea and tick medicine for pets may be killing birds and bees. The company stands to lose big if the chemical is banned.
Inovio's analysis of the VGX-3100 study omits an unknown number of patients, calling the results into question.
Thermo Fisher (TMO) beat analysts second quarter earnings estimates and raised its full year EPS guidance.
Leafly is a website that helps cannabis consumers research over 800 cannabis strains and find reputable locations to purchase the right strain.
Investors are still focused on the the looming approval of generic Copaxone.
The buyside "whisper number" for Sovaldi sales is $3.5 billion. But everyone who follows Gilead knows this, which means the "whispered" whisper number for sales is $4 billion or more.
Galena stands little chance of delivering higher sales of Zuplenz than its previous marketer.
Allergan is in a tight spot: It had better hope, if it's successful fighting off Valeant, that its stock price doesn't tumble -- and in a year has rebounded!
New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV